GlassScriptPhysician profile
Jacques P Ganem
NPI 1407896202
$4,757.05
in general payments reported to CMS, 2019-2025
32 companies · $783 in 2025
The $783 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $409 · 2021: $478 · 2022: $794 · 2023: $979 · 2024: $956 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $784.45 | 2019-2025 | Xtandi |
| Abbvie INC. | $599.59 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $377.48 | 2019-2024 | Provenge |
| Boston Scientific Corporation | $336.05 | 2019-2025 | General - Erectile Dysfunction, Lithovue, Axonics |
| Urogen Pharma, INC. | $319.89 | 2021-2025 | Jelmyto |
| Janssen Biotech, INC. | $288.28 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $282.91 | 2019-2023 | Xiaflex |
| Immunitybio, INC. | $156.75 | 2025 | |
| Blue Earth Diagnostics | $147.57 | 2020-2025 | Posluma |
| Myovant Sciences INC. | $147.12 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $147.08 | 2023 | Orgovyx |
| Calyxo, INC. | $125.52 | 2025 | Cvac Aspiration System |
| Travere Therapeutics, INC. | $120.99 | 2019 | |
| Myriad Genetic Laboratories, INC. | $120.60 | 2024 | Prolaris |
| Laborie Medical Technologies Corp. | $119.47 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $116.38 | 2019-2024 | Itind System |
| Neotract INC. | $90.14 | 2020 | |
| Pfizer INC. | $74.64 | 2019-2024 | |
| Bioprotect Medical, INC. | $72.37 | 2024-2025 | Bioprotect Balloon Implant System |
| Sun Pharmaceutical Industries INC. | $67.22 | 2022-2025 | |
| Angiodynamics, INC. | $42.46 | 2021-2022 | |
| Coloplast Corp | $27.25 | 2019-2025 | |
| Procept Biorobotics Corporation | $22.95 | 2024 | Aquabeam System |
| Tolmar Pharmaceuticals, INC. | $22.14 | 2022 | |
| Merck Sharp & Dohme LLC | $21.97 | 2023 | Keytruda, Welireg, Lynparza |
| Ferring Pharmaceuticals INC. | $21.63 | 2020 | |
| Clarus Therapeutics INC. | $21.34 | 2021 | |
| Smith+Nephew, INC. | $20.39 | 2022 | |
| Rochester Medical Corporation | $19.99 | 2022 | |
| Antares Pharma, INC. | $15.01 | 2024 | Xyosted |
| Ambu INC. | $14.16 | 2024 | |
| Cook Medical LLC | $13.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacques Ganem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.